# US 10,870,704 B2 · CD83 binding proteins and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,870,704 B2 - Document ID: US10870704B2 - Status: Granted - Kind: B2 - Application number: 15/521,124 - Filed: 2015-10-23 - Published: 2017-11-23 - Granted: 2020-12-22 - Earliest claimed: 2014-10-23 - Assignees: Kira Biotech Pty Limited - Applicants: Kira Biotech Pty Limited - Inventors: Joanne L. Casey; Andrew M. Coley - Web page: https://patentgrep.com/patent/US10870704B2 ## CPC - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 31/18: for HIV - A61P 35/00: Antineoplastic agents - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 16/2803: {against the immunoglobulin superfamily} - C07K 2317/21: from primates, e.g. man - C07K 2317/515: Complete light chain, i.e. VL + CL - C07K 2317/55: Fab or Fab' - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An isolated or recombinant CD83 binding protein may include an antigen binding domain, wherein the antigen binding domain binds specifically to CD83 or a cell expressing CD83. ## Claims ### Claim 1 A CD83 binding protein comprising an antigen binding domain which specifically binds to CD83, wherein the binding protein comprises: three heavy chain complementarity determining regions (VH CDRs) comprising amino acid sequences as shown in SEQ ID NO:3 (VH CDR1), SEQ ID NO:4 (VH CDR2), and SEQ ID NO:5 (VH CDR3); and (i) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:51 (VL CDR1), SEQ ID NO:52 (VL CDR2), and SEQ ID NO:53 (VL CDR3); or (ii) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:54 (VL CDR1), SEQ ID NO:55 (VL CDR2), and SEQ ID NO:56 (VL CDR3); or (iii) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:57 (VL CDR1), SEQ ID NO:58 (VL CDR2), and SEQ ID NO:59 (VL CDR3); or (iv) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:60 (VL CDR1), SEQ ID NO:61 (VL CDR2), and SEQ ID NO:62 (VL CDR3); or (v) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:63 (VL CDR1), SEQ ID NO:64 CDR2), and SEQ ID NO:65 (VL CDR3); or (vi) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:66 (VL CDR1), SEQ ID NO:67 CDR2), and SEQ ID NO:68 (VL CDR3); or (vii) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:69 (VL CDR1), SEQ ID NO:70 CDR2), and SEQ ID NO:71 (VL CDR3); or (viii) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:72 (VL CDR1), SEQ ID NO:73 CDR2), and SEQ ID NO:74 (VL CDR3); or (ix) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:75 (VL CDR1), SEQ ID NO:76 CDR2), and SEQ ID NO:77 (VL CDR3); or (x) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 CDR2), and SEQ ID NO:80 (VL CDR3); or (xi) three light chain complementarity determining regions (VL CDRs) comprising amino acid sequences as shown in SEQ ID NO:81 (VL CDR1), SEQ ID NO:82 CDR2), and SEQ ID NO:83 (VL CDR3); or (xii) three light chain complementarity determining regions CDRs) comprising amino acid sequences as shown in SEQ ID NO:84 (VL CDR1), SEQ ID NO:85 CDR2), and SEQ ID NO:86 CDR3). ### Claim 2 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein comprises a heavy chain variable region (VH) and a light chain variable region (VL) in a single polypeptide chain. ### Claim 3 (depends on 2) The CD83 binding protein of claim 2, wherein the binding protein is: a single chain Fv fragment (scFv); or (ii) a dimeric scFv (di-scFv); or (iii) (i) or (ii) linked to a Fc or a heavy chain constant domain (CH)2 and/or CH3; or (iv) (i) or (ii) linked to a protein that binds to an immune effector cell. ### Claim 4 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein comprises a heavy chain variable region (VH) and a light chain variable region (VL) in separate polypeptide chains. ### Claim 5 (depends on 4) The CD83 binding protein of claim 4, wherein the binding protein is: (i) a diabody; or (ii) a triabody; or (iii) a tetrabody; or (iv) a Fab; or (v) a F(ab′)2; or (vi) a Fv; or (vii) one of (i) to (vi) linked to a Fc or a CH2 and/or CH3; or (viii) one of (i) to (vi) linked to a protein that binds to an immune effector cell or (IX) an antibody. ### Claim 6 (depends on 5) The CD83 binding protein of claim 5, wherein the binding protein is an antibody. ### Claim 7 (depends on 6) The CD83 binding protein of claim 6, wherein the antibody comprises: (i) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:6; or (ii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:7; or (iii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:8; or (iv) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:9; or (v) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:10; or (vi) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:11; or (vii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:12; or (viii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:13; or (ix) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:14; or (x) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:15; or (xi) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:16; or (xii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:17. ### Claim 8 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein is a chimeric, de-immunized, humanized, synhumanized, human, primatized, or composite antibody. ### Claim 9 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein comprises an Fc region capable of inducing an enhanced level of effector function compared to a human IgG1 or IgG4 Fc region and/or an Fc region capable of conferring an extended half-life compared to a human IgG1 or IgG4 Fc region. ### Claim 10 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein competitively inhibits binding of an antibody to CD83 and/or binds to the same epitope on CD83 as an antibody, wherein the antibody comprises a heavy chain sequence as shown in SEQ ID NO:1 and a light chain sequence as shown in SEQ ID NO:31. ### Claim 11 (depends on 1) A conjugate binding protein comprising the CD83 binding protein of claim 1, wherein the binding protein is conjugated to a compound. ### Claim 12 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein is a naked binding protein. ### Claim 13 (depends on 1) A composition comprising the CD83 binding protein of claim 1, and a suitable carrier. ### Claim 14 (depends on 13) The composition of claim 13, wherein the carrier is pharmaceutically acceptable. ### Claim 15 (depends on 1) The CD83 binding protein of claim 1, wherein the binding protein comprises: (i) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:6; or (ii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:7; or (iii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:8; or (iv) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:9; or (v) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:10; or (vi) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:11; or (vii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:12; or (viii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:13; or (ix) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:14; or (x) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:15; or (xi) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:16; or (xii) a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:17. ### Claim 16 (depends on 15) The CD83 binding protein of claim 15, wherein the binding protein comprises a VH sequence as shown in amino acids 1 to 115 of SEQ ID NO:2 and a VL sequence as shown in SEQ ID NO:6. ### Claim 17 (depends on 16) The CD83 binding protein of claim 16, wherein the binding protein comprises a heavy chain sequence as shown in SEQ ID NO:1 and a light chain sequence as shown in SEQ ID NO:31.